Bob Duggan’s success shows you don’t need a Ph.D., or even a college education, to make money in the complex world of biotech ...

A dark money anti-pharma bus —A rare disease treatment approval for Zevra —An FTC lawsuit against pharmacy benefit managers ...

As a new regime and phase begin for the market and economy, after the FED cut interest rates by a surprising 50bps last ...

Investing in biotech stocks isn't for everyone. An unsuccessful clinical trial can cause a huge decline. The competition is ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

IPOs at three biotechs last week tempted insiders to make huge share purchases. This spilled over into buying at a couple of ...

Scott Rapoport earned his PhD in marine biology from Scripps Institution of Oceanography at UC San Diego in 2003. Drawn to ...

Ginkgo Bioworks is pivoting: Once a synthetic biology darling, the flailing company has now turned to AI-driven protein ...

The drop in interest rate is slightly bigger than anticipated and good news for the biotech industry, but little will change ...

The vaccine market might be a crowded one, but London-based Vicebio aspires to cement its own place within it. The startup ...

Moleculin Biotech shares were up 12% to $2.65 after the company said it saw positive in vivo efficacy data of Annamycin in lung metastatic models of sarcoma. The stock is approaching its 52-week low ...

The new firm is raising a $150 million fund to back startups around science emerging outside Boston and San Francisco.